Considering as monotherapy or in combination with metformin or each other, to date, GLP-1 RA and SGLT2i represent the best choice to modify CV profile in T2D patients with such clinical differences regarding PAD setting. The gene discussed is GLP1R; the disease is peripheral arterial disease.